On September 10, 2019 Be The Match BioTherapies, an organization offering solutions for companies developing and commercializing cell and gene therapies, and Celyad (Euronext Brussels and Paris, and Nasdaq: CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell therapies, reported a collaboration to advance the clinical trial of Celyad’s non-gene edited allogeneic CAR-T therapies (Press release, Be The Match BioTherapies, SEP 10, 2019, View Source [SID1234539412]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Through the collaboration, Be The Match BioTherapies will provide high-quality, consistent starting material from volunteer donors on the Be The Match Registry for the development and manufacturing of Celyad’s allogeneic CAR-T cell program.
"At Celyad, we are constantly pushing boundaries of innovation to develop our CAR-T cell therapies. We surround ourselves with partners who can help turn these ideas into product candidates for which logistical challenges are bound to rise," said Jean-Pierre Latere, chief operating officer of Celyad. "Partnering with Be The Match BioTherapies gives us starting material that meets the needs of our clinical development programs of non-gene edited allogeneic CAR-T candidate therapies."
As part of the National Marrow Donor Program/Be The Match, Be The Match BioTherapies will leverage extensive resources to support the trial, including access to more than 20 million donors through the Be The Match Registry, the world’s largest and most diverse registry of potential donors for hematopoietic stem cell transplant and cellular therapy starting material. Celyad will join Be The Match BioTherapies’ growing network of partners in the E.U., as Be The Match BioTherapies extends its cell therapy supply chain support to advance the rising number of cell and gene therapies worldwide.
"Celyad is among those leading the charge developing next-generation cellular therapies," said Mark Flower, vice president, Business Development and Strategic Partnerships, Be The Match BioTherapies. "The pioneering research at the company has allowed the field of allogeneic CAR-T therapies to take shape and become a reality. We look forward to supporting Celyad’s work to help bring transformative therapies to patients suffering from a broad range of cancers worldwide."